Homozygous Familial Hypercholesterolemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for homozygous familial hypercholesterolemia. 16 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
16
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Homozygous Familial Hypercholesterolemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 16 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating homozygous familial hypercholesterolemia. Each bar = one year. Y-axis scaled to peak year (7 patents).

3
29
7
38
6
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Caduet
Amlodipine Besylate
 Pfizer Inc. 16 63 — 2029-10-05

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10799487 Caduet method of use 75 2038-01-23
12226528 Caduet method of use 75 2041-02-24
12440441 Caduet method of use 75 2041-02-24
12005141 Caduet method of use 75 2041-02-24
11458095 Caduet method of use 70 2041-02-24
11253474 Caduet method of use 70 2041-02-24
11723866 Caduet method of use 70 2041-02-24
7846961 Caduet method of use 68 2029-10-05
7846961 Caduet method of use 68 2029-10-05
7846961 Caduet method of use 68 2029-10-05

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10350171 Caduet formulation 42 2038-06-14
10350171 Caduet formulation 42 2038-06-14
10350171 Caduet formulation 42 2038-06-14
10322117 Caduet formulation 55 2038-01-23
12465599 Caduet formulation 55 2038-01-23
12465599 Caduet formulation 55 2038-01-23
7846961 Caduet method of use 68 2029-10-05
7846961 Caduet method of use 68 2029-10-05
7846961 Caduet method of use 68 2029-10-05
11458095 Caduet method of use 70 2041-02-24

Related